News for LCI Stock

Lannett Company, Inc. Enters Into Restructuring Support Agreement NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS LANNETT SHARES UPDATE LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2 LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24 LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4 LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14 LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3 LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year Guidance Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3 Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25 LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler® Lannett Launches Fluvastatin Sodium ER Tablets Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing Lannett Announces Fiscal 2021 Third-Quarter Financial Results Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5 Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026 Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026 Lannett Submits ANDA For Generic ADVAIR DISKUS® Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3 Lannett Announces New $30 Million Revolving Credit Facility Lannett Pays Off, In Full, Remaining Term A Loans Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules) Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4 Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results Lannett To Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Wednesday, August 26 Lannett Announces Notice Of Proposed Settlement And Dismissal With Prejudice Of Derivative Action Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus® Lannett Launches Mexiletine HCl Capsules Lannett Announces Restructuring, Cost Reduction Initiatives Lannett To Launch Levorphanol Tablets Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine Lannett Announces Launch Of FDA Approved Levothyroxine Tablets